Dyne Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2018-01-01
- Employees
- 141
- Market Cap
- $4.4B
- Website
- http://www.dyne-tx.com
- Introduction
Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.
Pfizer Phase III DMD Gene Therapy Study Misses Goal
Pfizer's phase III study on fordadistrogene movaparvovec for Duchenne muscular dystrophy (DMD) failed primary and key secondary endpoints. The therapy aimed to improve motor function in boys aged 4-8. Despite safety concerns, Pfizer plans to share detailed results soon. Sarepta Therapeutics leads the DMD treatment market.
© Copyright 2025. All Rights Reserved by MedPath